Navigation Links
Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at AACR Annual Meeting
Date:3/16/2009

normal prostate tissues. Evidence of reovirus spread to other intraprostatic cancerous lesions was not observed.

The investigators concluded that reovirus therapy may provide a novel treatment for prostate cancer, however, ongoing work to circumvent immune clearance of reovirus is required. A poster presentation is scheduled to be delivered by Dr. Don Morris and his research group from the Tom Baker Cancer Centre, Calgary, on Tuesday, April 21, 2009.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the implication of the abstracts and materials presented on the AACR website and at this meeting with respect to REOLYSIN(R), the Company's expectations related to the results of trials investigating delivery of REOLYSIN(R), and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize RE
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Lake, MN (PRWEB) May 21, 2013 The ... trade show display solution for sales and marketing teams looking ... Displays describes the kit as “everything you’ll need to ... Fusion Fabric Display Kit comes with a number of displays ... all-around trade booth 20 feet by 20 feet in size. ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 Oven Industries ... with ramp/soak capabilities. The 5R6-900 benchtop controller has many ... device can be plugged into the wall as a ... supply. This distinctive detail makes the device unique, as ... The laboratory temperature controller can also be used universally, ...
(Date:5/20/2013)... 20, 2013  Dr. Gerald Zon ... research, recently launched a new blog in conjunction with ... zon.trilinkbiotech.com ), focuses on what,s trending in the field ... thought leaders, discussions of research presented at conferences and ... Dr. Zon (PhD Princeton University 1971) developed automated ...
(Date:5/20/2013)... CHAPEL HILL, N.C. , May 20, 2013 ... pharmaceutical company focused on developing differentiated antibiotics to ... bacterial infections, today announced that it presented data ... 2013) in Philadelphia demonstrating ... versus levofloxacin in Cempra,s prior Phase 2 clinical ...
Breaking Biology Technology:GLM Displays Announces All-in-One Formulate Fusion Fabric Display Kit 2New Laboratory Temperature Controller by Oven Industries 2Dr. Gerald 'Jerry' Zon Launches New Blog for TriLink BioTechnologies 2Cempra Presents Post-Phase 2 Analysis of Solithromycin's Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP) 2
... July 5, 2011 Cellectis bioresearch, a subsidiary ... customization, has received the "Most Innovative New Service ... Access service offering. TALENs(1) allow for customized gene ... powerful and now affordable new tool. This prize ...
... 2011 Genesis Biopharma, Inc. (OTC/BB: GNBP), a ... Laszlo Radvanyi, Ph.D., an Associate Professor in the ... University of Texas MD Anderson Cancer Center in ... Board.  MD Anderson is one of the world,s ...
... 5, 2011 Cord Blood America, Inc . (OTC ... entered into an agreement with Regence ( www.regence.com/index.jsp ) to ... its BlueCross and BlueShield plans in Idaho, Oregon, Utah and ... BlueShield (BCBS) licensee contracts. The partnership gives Regence ...
Cached Biology Technology:TALEN® Access by Cellectis Bioresearch Receives "Most Innovative New Service 2011" Award at Life Science Awards 2Laszlo Radvanyi, Ph.D. Joins Genesis Biopharma Scientific and Medical Advisory Board 2Laszlo Radvanyi, Ph.D. Joins Genesis Biopharma Scientific and Medical Advisory Board 3Cord Blood America Enters Agreement With Regence, Serving BlueCross and BlueShield Programs in the Northwest U.S. and Mountain Regions 2
(Date:5/20/2013)... MINNEAPOLIS/ST. PAUL (MAY 20, 2013) University of Minnesota ... of Minnesota, in partnership with the University,s Brain Tumor ... peripheral nerve sheath tumors (MPNST) that allow them to ... of cancer. , The research was published this week ... the Sleeping Beauty transposon method, researchers in the lab ...
(Date:5/20/2013)... The Amazon rain forest, popularly known as the lungs of ... use carbon dioxide from the air to grow parts that ... away by the region,s plentiful rainfall. , Until recently ... the Amazon River and ended up deep in the ocean. ... exhale huge amounts of carbon dioxide though left open ...
(Date:5/20/2013)... - A National Science Foundation (NSF) planning grant will ... (CARD), a joint program of the University of Illinois ... Mass. , "CARD will be devoted to research in ... agricultural products; forestry and paper products; chemical products; textiles; ... professor of food science and human nutrition and the ...
Breaking Biology News(10 mins):U of M researchers develop model for better testing, targeting of MPNST 2Amazon River exhales virtually all carbon taken up by rain forest 2Amazon River exhales virtually all carbon taken up by rain forest 3NSF approves planning grant for Center for Advanced Research in Drying 2
... , A series of papers published this month on ecological ... by the University of Colorado Boulder in the high mountains ... seasonal snow and ice are the most sensitive to changes ... April issue of the journal BioScience. The papers were ...
... Ga. Soldiers in war zones and farmers tending their ... impact their nerves. In large doses these agents, called ... can also produce chronic disabilities such as problems with learning ... Terry Jr., pharmacologist at the Medical College of Georgia at ...
... Clean drinking water and basic sanitation are human rights. ... have no access to drinking water and some 2.6 ... also an important economic factor: Today, agricultural and manufacturing ... this precious commodity. And the demand for water continues ...
Cached Biology News:CU research shows warming climate threatens ecology at mountain research site west of Boulder 2CU research shows warming climate threatens ecology at mountain research site west of Boulder 3Effect of chronic exposure to chemicals used as weapons, pesticides under study 2Effect of chronic exposure to chemicals used as weapons, pesticides under study 3Use less water, producing energy and fertilizer at the same time 2Use less water, producing energy and fertilizer at the same time 3
RABBIT ANTI HUMAN ALPHA-2-ANTIPLASMIN...
... DNA Polymerase with a proprietary thermostable proofreading ... than standard Taq DNA polymerase, Double the ... DNA templates >20kb, Concentration: 5U/ul, Applications: high ... and mutagenesis We are part of Thermo ...
... EnzChek Lysozyme Assay Kit (E-22013) provides,researchers ... levels of lysozyme,activity in solution. This ... to 20 U/mL (Figure 1). The ... cell,walls, which are labeled to such ...
... based on measurenment of enzyme activity of ... microtiter plate. The procedure includes two incubation ... 2nd enzyme reaction) separated by a ... the determination of human enzymaticaly active TRAP ...
Biology Products: